Pfizer’s sasanlimab combo significantly improves event-free survival in BCG-naïve, high-risk non-muscle invasive bladder cancer: New York Tuesday, April 29, 2025, 14:00 Hrs [IS ...

NEW YORK, April 26, 2025--Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination ...

Pfizer Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Scrap for the year ending 31-Mar-2024.For the quarter ended 31-12-2024, the company has reported a Standalone Total ...